p53 mutation and MDM2 amplification frequency pediatric rhabdomyosarcoma tumors and cell lines

Medical and Pediatric Oncology

Volumn 35, Issue 2, 2000, Pages 96-103

  Mora, Jaume ^a   Dobrenis, Andrea M ^b   Bussel, James B ^b   Aledo, Alex ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; MDM2; p53; Rhabdomyosarcoma; SSCP analysis

Indexed keywords

ANTINEOPLASTIC A; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOSARCOMA; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, SOUTHERN; CELL LINE; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; EXONS; GENE AMPLIFICATION; HUMAN; INFANT; MUTATION; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROTEIN P53; PROTO-ONCOGENE PROTEINS; RHABDOMYOSARCOMA; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033861106     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z     Document Type: Article

References (40)

1. Biology and therapy of pediatric rhabdomyosarcoma
2. Pathology of rhabdomyosarcoma: Experience of the Intergroup Rhabdomyosarcoma Study, 1972-78
3. Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood
4. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma
5. P-glycoprotein and multidrug resistance
6. p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs
7. p53, the cellular gatekeeper for growth and division
8. p53, Guardian of the Genome
9. The p53 tumor suppressor gene
10. A comparison of the biological activities of wild-type and mutant p53
11. p53 and response to chemotherapy and radiotherapy
12. p53 Mutation and MDM2 amplification in human soft tissue sarcomas
13. Amplification of a gene encoding a p53-associated protein in human sarcomas
14. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
15. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
16. Mdm2 promotes the rapid degradation of p53
17. Regulation of p53 stability by Mdm2
18. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents
19. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents
20. Rhabdomyosarcoma-specific expression of the Herpes Simplex Virus thymidine kinase gene confers sensitivity to ganciclovir
21. Detection of p53 mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products
22. A variation in the structure of the protein-coding region of the human p53 gene
23. Single strand conformational polymorphism (SSCP) analysis of the 170 kDa isozyme of DNA topoisomerase II in human tumor cells
24. Mutation of the p53 gene in human soft tissue sarcomas: Association with abnormalities of the RB1 gene
25. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma
26. Selective sensitization to DNA damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p53 overexpression
27. Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status
28. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer
29. Short alternatively spliced transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms
30. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein
31. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
32. Interaction between the retinoblastoma protein and the oncoprotein MDM2
33. Amplification of MDM2 inhibits MyoD-mediated myogenesis
34. Regulation of the p53 protein by the MDM2 oncoprotein
35. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents intereaction with p53
36. MDM2 gene amplification and expression in non-small-cell lung cancer: Immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation
37. Mechanisms of p53 loss in human sarcomas
38. Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors
39. Mutation analysis of p53 gene in childhood malignant solid tumors